Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680544 | 0.87 | PTGS2 (0.48) | PTGS2PTGS1MAPK14CSNK1DMAPK10 | |
| SCHEMBL4680219 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1MAPTMAPK14TDP1 | |
| SCHEMBL4684085 | 0.80 | MAPK10 (0.46) | PTGS2PTGS1MAPTMAPK10 | |
| SCHEMBL14591610 | 0.76 | PTPN1 (0.36) | MAPTMAPK10TDP1L3MBTL1 | |
| SCHEMBL4680304 | 0.73 | MAPK14 (0.45) | PTGS2PTGS1MAPK14CSNK1DMAPK10 | |
| SCHEMBL4993 | 0.70 | NOTUM (0.48) | — | |
| SCHEMBL30375140 | 0.70 | NOTUM (0.48) | — | |
| SCHEMBL14591605 | 0.69 | PTGS2 (0.47) | PTGS2PTGS1MAPTTDP1L3MBTL1 | |
| SCHEMBL22827984 | 0.69 | PTGS2 (0.66) | PTGS2PTGS1 | |
| SCHEMBL14143223 | 0.69 | PTPN1 (0.35) | MAPTMAPK10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218369-B1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1218369-A4 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTX PHARMACEUTICALS INCORPORATED | 2003-08-07 | — | — | US | disclosed |
| EP-1218369-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012621-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | MAPK1, PACSIN2, MAP3K1 | PTGS2 851/4885PTGS1 736/4885ESR1 2575/4885 |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | PTGS2 461/4885PTGS1 1001/4885ESR1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.